312 related articles for article (PubMed ID: 7381862)
21. Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.
Salminen L; Lindberg R; Toivari HR; Huupponen R; Kaila T; Iisalo E
Int Ophthalmol; 1989 Jan; 13(1-2):91-3. PubMed ID: 2787298
[TBL] [Abstract][Full Text] [Related]
22. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
[TBL] [Abstract][Full Text] [Related]
23. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
[TBL] [Abstract][Full Text] [Related]
24. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Sommers DK; Moncrieff J; Avenant J
Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
[TBL] [Abstract][Full Text] [Related]
25. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
Gleiter CH; Aichele G; Nilsson E; Hengen N; Antonin KH; Bieck PR
Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
[TBL] [Abstract][Full Text] [Related]
26. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
Veronese ME; McLean S
Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734
[TBL] [Abstract][Full Text] [Related]
27. Polymorphic oxidation of debrisoquine in bladder cancer.
Benítez J; Ladero JM; Fernández-Gundín MJ; Llerena A; Cobaleda J; Martínez C; Muñoz JJ; Vargas E; Prados J; González-Rozas F
Ann Med; 1990 Jun; 22(3):157-60. PubMed ID: 2393550
[TBL] [Abstract][Full Text] [Related]
28. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
29. Poor metabolisers of debrisoquine reveal their true colours.
Idle JR
Lancet; 1989 Nov; 2(8671):1097. PubMed ID: 2572815
[No Abstract] [Full Text] [Related]
30. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
Lennard MS; McGourty JC; Silas JH
Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891
[TBL] [Abstract][Full Text] [Related]
31. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.
Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL
Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370
[TBL] [Abstract][Full Text] [Related]
32. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.
Mahgoub A; Idle JR; Smith RL
Xenobiotica; 1979 Jan; 9(1):51-6. PubMed ID: 760321
[TBL] [Abstract][Full Text] [Related]
33. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.
Heim M; Meyer UA
Lancet; 1990 Sep; 336(8714):529-32. PubMed ID: 1975039
[TBL] [Abstract][Full Text] [Related]
34. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
35. Polymorphic oxidation of debrisoquine and sparteine.
Eichelbaum M
Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
[No Abstract] [Full Text] [Related]
36. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
[TBL] [Abstract][Full Text] [Related]
37. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Eichelbaum M; Bertilsson L; Säwe J
Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
[TBL] [Abstract][Full Text] [Related]
38. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL
Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168
[TBL] [Abstract][Full Text] [Related]
39. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
40. Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Philip PA; Lewis LD; James CA; Rogers HJ
Cancer Chemother Pharmacol; 1988; 22(4):321-4. PubMed ID: 3168145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
